Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ONCE

Spark Therapeutics (ONCE) Stock Price, News & Analysis

Spark Therapeutics logo

About Spark Therapeutics Stock (NASDAQ:ONCE)

Key Stats

Today's Range
$0.18
$0.18
50-Day Range
$110.05
$113.57
52-Week Range
$34.53
$114.20
Volume
N/A
Average Volume
891,560 shs
Market Capitalization
$6.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.

Receive ONCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spark Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ONCE Stock News Headlines

Trump won. Buy this coin now.
Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.
See More Headlines

ONCE Stock Analysis - Frequently Asked Questions

Spark Therapeutics Inc (NASDAQ:ONCE) posted its quarterly earnings data on Tuesday, August, 7th. The biotechnology company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.34. The biotechnology company had revenue of $25.19 million for the quarter, compared to analyst estimates of $29.44 million. Spark Therapeutics had a negative trailing twelve-month return on equity of 59.10% and a negative net margin of 358.41%.

Spark Therapeutics (ONCE) raised $88 million in an IPO on Friday, January 30th 2015. The company issued 5,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Spark Therapeutics investors own include Bristol-Myers Squibb (BMY), NVIDIA (NVDA), Brainstorm Cell Therapeutics (BCLI), Meta Platforms (META), Alibaba Group (BABA), Gilead Sciences (GILD) and Micron Technology (MU).

Company Calendar

Last Earnings
8/07/2018
Today
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ONCE
Fax
N/A
Employees
368
Year Founded
N/A

Profitability

Net Income
$-78,820,000.00
Net Margins
-358.41%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$64.72 million
Book Value
$13.15 per share

Miscellaneous

Free Float
N/A
Market Cap
$6.94 million
Optionable
No Data
Beta
2.05
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:ONCE) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners